Biomarin Pharmaceutical reported $56.67M in EBITDA for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Acadia Pharmaceuticals ACAD:US $ -112.5M 68.38M
Acorda Therapeutics ACOR:US $ -4.97M 3.28M
Agios Pharmaceuticals AGIO:US $ -98.67M 3.96M
Alnylam Pharmaceuticals ALNY:US $ -137.27M 45.91M
Amgen AMGN:US $ 3341M 185M
Biogen BIIB:US $ 674.7M 20.2M
Biomarin Pharmaceutical BMRN:US $ 56.67M 96.56M
Insmed INSM:US $ -98173000 1.78M
IONIS PHARMACEUT IONS:US $ -53.21M 278.25M
Sangamo Biosciences SGMO:US $ -42.43M 5.29M
Ultragenyx Pharmaceutical RARE:US $ -132.54M 33.51M
United Therapeutics UTHR:US $ 300.5M 117.1M